These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35363628)

  • 1. Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.
    Bronsky J; Copova I; Kazeka D; Lerchova T; Mitrova K; Pospisilova K; Sulovcova M; Zarubova K; Hradsky O
    Clin Transl Gastroenterol; 2022 May; 13(5):e00490. PubMed ID: 35363628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
    Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
    Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
    Macaluso FS; Fries W; Privitera AC; Cappello M; Siringo S; Inserra G; Magnano A; Di Mitri R; Mocciaro F; Belluardo N; Scarpulla G; Magrì G; Trovatello A; Carroccio A; Genova S; Bertolami C; Vassallo R; Romano C; Citrano M; Accomando S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Porcari S; Ferracane C; Cottone M; Orlando A;
    J Crohns Colitis; 2019 Feb; 13(2):209-217. PubMed ID: 30295785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
    Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
    Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of infliximab with adalimumab in biologic-naïve patients with Crohn's disease: a single-center 13-year experience.
    Erdoğan Ç; Durak MB; Alkan A; Kılıç V; Kıvrakoğlu F; Koşar K; Yuksel I
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5757-5766. PubMed ID: 37401312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation of biologics in Crohn's disease: critical review of observational studies.
    Einarson TR; Bereza BG; Ying Lee X; Lelli F
    Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study.
    Tursi A; Elisei W; Picchio M; Zampaletta C; Pelecca G; Faggiani R; Brandimarte G
    Tech Coloproctol; 2014 Nov; 18(11):1041-6. PubMed ID: 24915941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
    Fumery M; Jacob A; Sarter H; Michaud L; Spyckerelle C; Mouterde O; Savoye G; Colombel JF; Peyrin-Biroulet L; Gower-Rousseau C; Turck D;
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):744-8. PubMed ID: 26000887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
    Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease.
    Jung YS; Han M; Park S; Cheon JH
    Gut Liver; 2021 Jan; 15(1):92-99. PubMed ID: 32839359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.